Form 4: Acurx Pharmaceuticals Director Robert DeLuccia Granted Stock Options

Robert DeLuccia, a director of Acurx Pharmaceuticals, was granted stock options to purchase 250,000 shares of the company's common stock on February 5, 2025.

Summary

• On February 5, 2025, Robert J. DeLuccia, a director of Acurx Pharmaceuticals, Inc., was granted stock options.
• The stock options allow DeLuccia to purchase 250,000 shares of Acurx Pharmaceuticals' common stock at an exercise price of $0.7982 per share.
• The options vest immediately and expire on February 5, 2035.
• The transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants. It's neutral in tone and doesn't inherently indicate positive or negative sentiment, but the granting of options can be seen as a positive sign of aligning director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting may incentivize the director to contribute to the company's success in the near term.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• The size of the grant (250,000 shares) and the vesting schedule (immediate) would need to be compared to similar grants at comparable companies to assess its relative value and incentive structure.
• Companies like BioCryst Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated also use stock options as part of their compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Acurx Pharmaceuticals, Robert DeLuccia, beneficial ownership, insider trading